Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma | OncLive

Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma

June 8, 2020

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Jessica Hergert.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Omid Hamid, MD, to discuss some of the most noteworthy data in melanoma that were presented during the 2020 ASCO Virtual Scientific Program.

In our exclusive interview, Dr. Hamid, director of the Melanoma Center and Phase I Immuno-Oncology Program and chief of Immunotherapy and Translational Research at The Angeles Clinic and Research Institute, highlighted key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Additionally, Dr. Hamid shed light on data showing the feasibility of talimogene laherparepvec (T-VEC; Imlygic) in patients with liver metastases, as well combinations leading to increased T-cell infiltration.


x